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Abstract
Background: Apart from stroke, atrial fibrillation (AF) is associated with higher mortality and heart 
failure (HF), in which risk stratification scheme is lacking. Therefore this investigation examined the 
prognostic value of echocardiographic predictors against CHA2DS2-VASc score in permanent non-
-valvular AF (NVAF). 
Methods: In 252 asymptomatic or mildly symptomatic consecutive patients with NVAF, comprehensive  
echocardiography was performed. Left atrial deformation parameters were also obtained by two-dimen-
sional speckle tracking echocardiography. End-points pertaining to HF deterioration, ischemic stroke 
and cardiac death were recorded.
Results: There were 74 cardiovascular events, including 44 deterioration of HF, 22 ischemic strokes 
and 8 cardiovascular deaths during an average follow-up period of 20.8 ± 13.5 months (interquartile 
range, 8–31 months). For prediction of overall prognosis and HF, left ventricular mass index, peak early 
filling velocity (E), and E to tissue Doppler mitral annular early diastolic velocity ratio (E/e’) outper-
formed CHA2DS2-VASc score in multivariate analysis, area under curve, and stepwise nested regression 
models. Left ventricular hypertrophy and E/e’ > 8 showed worse overall and heart-failure free survival 
in Kaplan-Meier curves. For prediction of ischemic stroke, the addition of E or E/e’ to CHA2DS2-VASc 
score provides extra prognostic value. 
Conclusions: Echocardiographic parameters offer incremental value over CHA2DS2-VASc score for 
prediction of future cardiac events in NVAF. (Cardiol J 2018; 25, 1: 60–71)
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Introduction
Atrial fibrillation (AF) is one of the most 
common arrhythmias confronted in daily practice; 
affecting 1.5–2% of the general population in the 
developed world [1]. It is notorious for undermin-
ing the quality of life and increasing relevant car-
diovascular risks including a 5-fold risk of stroke, 
a 3-fold incidence of congestive heart failure (HF), 
and higher mortality [1]. In the aging population, 
AF is emerging as a major public health burden. 
Currently, most efforts have been dedicated to 
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stroke prediction and prevention on the basis of 
CHA2DS2-VASc score. On the other hand, AF as-
sociated cardiac mortality and HF exacerbation are 
clinically challenging issues which are frequently 
encountered. The analysis of the Randomized 
Evaluation of Long-Term Anticoagulant Therapy 
(RE-LY) study by Marijon et al. [2] surprisingly 
pointed out that cardiac death, but not stroke-
associated death, is responsible for 37% of death 
in AF. Among which, progressive HF is an impor-
tant determinant. It suggests that studying the 
contributors of AF-related adverse cardiac events 
and HF is as paramount as that of stroke. Although 
CHA2DS2-VASc score appears to be helpful in this 
aspect by some studies [3, 4], it was not gener-
ally applied for this purpose. In addition, current 
guidance does not stress HF prediction and there 
lacks a risk scheme to tackle this conundrum [5]. 
Since cardiac ultrasound is a noninvasive and eas-
ily assessable tool, the possibility of implementing 
echocardiographic parameters in risk assessment 
for AF related adverse cardiac events is of par-
ticular interest and needs further characteriza-
tion. Indeed, several echocardiographic indexes 
pertaining to stroke risk stratification in AF have 
already been reported, namely the left atrial (LA) 
volume index (LAVi), LA appendage flow velocity, 
or LA deformation analysis [6–8]. This implies that 
incorporation of echocardiographic parameters to 
a clinical risk scheme to lower disease burden is 
of potential benefit. Also, CHA2DS2-VASc score is 
almost routinely obtained in every patient with 
AF, rendering comparison to echocardiographic 
indexes feasible. 
Accordingly, an undertaking with this study 
had interests focused on echocardiographic indexes 
in predicting: (1) overall adverse cardiac events, 
(2) HF progression and, (3) ischemic stroke against 
CHA2DS2-VASc score in permanent non-valvular 
AF (NVAF). 
Methods
Study population
Between December 2010 and June 2014, 
we screened 950 consecutive patients who had 
permanent NVAF (no coexistent aortic or mitral 
valve disease more than a mild degree) and had 
undergone a clinically indicated echocardiography 
in the outpatient clinic of National Cheng Kung 
University Hospital (Fig. 1). Permanent AF was 
diagnosed according to the guidelines described by 
the European Society of Cardiology and European 
Heart Rhythm Association [1]. Serial electro-
cardiograms, Holter recordings, and the medical 
records were used to confirm that AF had lasted 
for more than 1 year. Patients excluded were those 
with: (1) New York Heart Association functional 
classification (NYHA) III or IV, (2) infiltrative car-
diomyopathy, (3) prior open heart surgery, (4) pace-
maker implantation, (5) congenital heart disease, 
(6) end-stage renal disease or liver cirrhosis, and 
(7) malignancy. Patients with incomplete image 
acquisition and less than 6-month follow-up were 
not enrolled (Fig. 1). Every 1 to 3 months, patients 
were followed up by their original care physicians 
blinded to the study in the clinic where symptoms 
and signs of HF as well as ischemic stroke events 
Figure 1. The study flow diagram; LVEF — left ventricular ejection fraction; NYHA — New York Heart Association. 
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were carefully evaluated. The baseline functional 
classification, medication, as well as comorbid 
conditions for calculation of the CHA2DS2-VASc 
score (including congestive HF or left ventricular 
[LV] dysfunction, hypertension, diabetes, history 
of stroke and vascular disease) were obtained from 
the medical records. The study end-points during 
the follow-up period were also obtained from the 
medical records or telephone interview and were 
adjudicated by two cardiologists. The end-points 
were designated as: (1) a composite of sudden car-
diac death, ischemic stroke, and HF exacerbation 
(symptom progression with evidence of pulmonary 
congestion by the X-ray either requiring hospitali-
zation or identified in the outpatient clinic), (2) HF 
exacerbation, and (3) ischemic stroke. Ischemic 
stroke was confirmed by a focal neurologic deficit 
of sudden onset and the computed tomography 
imaging findings. During the follow-up period, the 
time to each end-point was recorded separately 
and the time to the first end-point (if the patient 
had more than 1) was used for analysis. If patients 
experienced any cardiac events eventually leading 
to cardiovascular death, the end-point was denoted 
as that cardiac event but not death. All patients 
were followed until death or until the last contact.
The minimal follow-up period was 6 months. The 
follow-up rate was 94% as of January 2015.
The study adhered to the Declaration of Hel-
sinki and received approval from the Human Re-
search and Ethics Committee (A-ER-102-322) of 
National Cheng Kung University Hospital, where 
the informed consent was waived due to the ret-
rospective nature of this study. 
Standard echocardiography
Standard echocardiography was performed 
with Doppler studies (Vivid 7, GE-VingMed, Hort-
en, Norway) with a 3.5-MHz multiphase array 
probe in individuals lying in a left lateral decubitus 
position to obtain electrocardiogram-gated images. 
Standard M-mode, two-dimensional (2D), color, 
pulsed and continuous wave Doppler images were 
recorded and saved in a cine-loop format for five 
cardiac cycles with a frame rate of 50–90 frames 
per second. The images were analyzed offline with 
a dedicated software (EchoPac PC 09, GE-VingMed, 
Horten, Norway). The mean of measurements for 
5 beats was used for analysis.
All chamber quantification was aligned with 
the American Society of Echocardiography [9]. LV 
end-diastolic volume (LVEDV) and LV end-systolic 
volume (LVESV), which were measured from the 
apical 4- and 2-chamber views using Simpson’s 
biplane method, were indexed by the body surface 
area to obtain LVEDV index (LVEDVi) and LVESV 
index (LVESVi) [10]. LV mass was measured at 
end-diastole on M-mode recordings obtained in the 
parasternal long-axis view and calculated with the 
Devereux formula [3]. LV hypertrophy (LVH) was 
defined as LV mass index (LVMi) ≥ 115 g/m2 in 
men and ≥ 95 g/m2 in women [10]. The maximal 
LA volume during LV end-systole (LAVs) and the 
minimal LA volume during LV end-diastole (LAVd) 
were used to calculate LA total emptying fraction 
(LAEF), signified as [(LAVs – LAVd) / LAVs] × 
× 100% [3]. LAVi was obtained by LAVs indexed 
by body surface area. The sphericity of LA was 
assessed by LA eccentricity index (LAEi) [11]. Pa-
rameters of LV diastolic function were determined 
from transmitral inflow velocities using pulsed 
wave Doppler recordings in the apical 4-chamber 
view. Early mitral inflow velocity (E) was measured 
and peak mitral annular tissue Doppler velocity 
(e’) was obtained from septal and lateral mitral 
annulus to calculated mean e’. Subsequently, E/e’ 
ratio was derived with a normal value signified as 
E/e’ ≤ 8 [12].
Deformation analysis of LV and LA  
by speckle-tracking echocardiography
The global longitudinal stain (GLS) of LV was 
measured from three apical views by automated 
function imaging software as reported in detail 
previously with very low intra-observer and inter-
observer variability [13]. The method for LA defor-
mation analysis by speckle tracking echocardiog-
raphy has been described in detail in our previous 
studies [14, 15]. In patients with AF, we analyzed 
only the peak systolic positive strain (LAeR) and 
strain rate (LASRR) during LA filling (reservoir 
phase), and the peak negative conduit strain rate 
(LASRCD) in LV early filling while discarding the 
contractile strain and strain rate (peak negative 
strain and strain rate after the P-wave) [14]. The 
LA wall was further divided into 8 segments includ-
ing basal septal, middle septal, basal lateral, and 
middle lateral segments on a 4-chamber view and 
basal inferior, middle inferior, basal anterior, and 
middle anterior segments on a 2-chamber view. 
The averages of the LAeR, LASRR, and LASRCD in 
8 segments were recorded. The mean of measure-
ments for 5 cardiac cycles was used for analysis.
Observer variability 
The intra- and inter-observer variability of 
echocardiographic parameters were assessed in 
20 randomly selected patients and presented as the 
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percent variability (percentage of the absolute dif-
ference divided by the mean of repeated measure-
ments) and intraclass correlation coefficient (ICC). 
Statistical analysis
Statistical analysis was performed using SPSS 
version 18.0 (SPSS Inc., Chicago, Illinois) or JMP 
version 11.0 (SAS Institute Inc, Cary, NC). All data 
were presented as mean ± standard deviation 
unless otherwise stated. By using the c2 test for 
categorical variables, and independent-samples 
t-test for continuous variables, we first identified 
factors with significant correlations to enter mul-
tivariate logistic regression analysis (p < 0.05). 
To determine whether echocardiographic param-
eters could predict the end-points as compared to 
CHA2DS2-VASc score while avoiding colinearity 
between them, separate multivariate Cox regres-
sion models were employed for each echocardio-
graphic parameter. Incremental model performance 
was assessed by the change in the c2 value using 
sequential Cox analysis with nested models. The 
Kaplan-Meier method was used with a log-rank test 
to demonstrate differences between strata in terms 
of end-points. A p value of < 0.05 was considered 
to be statistically significant.
Results 
A total of 252 patients (mean age 67.8 ± 13.5 
years, 68% men) with NVAF formed our study 
group (Fig. 1, Table 1). Antiplatelet or anticoagulant 
use in the population is 54% and 25%, reflecting 
a general under-use of anticoagulant therapy as 
stated in a nationwide study in Taiwan [16]. Trivial 
tricuspid regurgitation with faint trans-tricuspid 
valve continuous wave Doppler tracings occurred 
in 30 patients, causing inaccuracy in estimating 
pulmonary arterial systolic pressure (PASP), hence 
PASP was not included in analysis. After a mean 
follow-up period of 20.8 ± 13.5 months (interquar-
tile range, 8–31 months), 74 (29%) patients reached 
the composite end-point of cardiovascular death 
(n = 8, all sudden cardiac death), HF exacerbation 
(n = 44) and ischemic stroke (n = 22). 
Differentiation of patients  
with or without end-points 
Patients with composite end-points had more 
severe LVH, higher E, E/e’, LAV, and CHA2DS2-
-VASc score. Patients with HF progression had 
more severe LVH and higher E/e’. On the other 
hand, patients with ischemic stroke had higher E, 
E/e’ and CHA2DS2-VASc score. Age, NYHA clas-
sification, anticoagulant use, heart rate, blood pres-
sure, LAEF, LAEi, LA deformation parameters, LV 
Table 1. Baseline characteristics of 252 patients. 
Age [years] 67.8 ± 13.5
Body mass index [kg/m2] 25.6 ± 4.74
Men 172 (68%)
Hypertension 175 (69%)
Diabetes mellitus 61 (24%)
Hyperlipidemia 136 (54%)
Current smoker 25 (10%)
Peripheral arterial occlusive disease 10 (4%)
Coronary artery disease 22 (9%)
NYHA I 151 (60%)
NYHA II 101 (40%)
Antiplatelet agents 136 (54%)
Anticoagulants 63 (25%)
Beta-blockers 102 (41%)
ACEI and/or ARBs 124 (49%)
Statins 37 (15%)
Diuretic use 96 (38%)
Heart rate [bpm] 83.5 ± 18.5
Systolic BP [mm Hg] 129.4 ± 17.1
Diastolic BP [mm Hg] 77.9 ± 12.7
LVEDVi [mL/m2] 41.10 ± 16.46
LVESVi [mL/m2] 19.14 ± 12.79
LVMi [g/m2] 101.72 ± 34.45
LVEF [%] 55.39 ± 12.69
LV GLS [%] –12.47 ± 4.66
E [m/s] 1.00 ± 0.25
DT [ms] 144.60 ± 41.66
E/e’ 10.40 ± 4.31
LAVi [mL/m2] 46.40 ± 18.04
LAEi 1.28 ± 0.15
LAEF [%] 23.81 ± 11.70
LAeR [%] 15.35 ± 7.53
LASRR [1/s] 1.37 ± 0.43
LASRCD [1/s] –1.86 ± 0.67
CHA2DS2-VASc score 2.90 ± 1.63
CHADS2 score 2.00 ± 1.34
Data are expressed as mean ± standard deviation or number (%). 
NYHA — New York Heart Association; ACEI — angiotensin-con-
verting enzyme inhibitor; ARB — angiotensin II receptor blocker; 
BP — blood pressure; DT — deceleration time; LA — left atrial;  
LV — left ventricular; LVEDVi — LV end-diastolic volume index; 
LVESVi — LV end-systolic volume index; LVMi — LV mass index; 
LVEF — LV ejection fraction; LV GLS — global LV peak systolic 
longitudinal strain; E — transmitral peak early filling velocity; 
E/e’— early trans-mitral velocity to tissue Doppler mitral annular 
early diastolic velocity ratio; LAVi — LA volume index; LAEi — LA 
eccentricity index; LAEF — LA ejection fraction; LAeR — LA reservoir 
strain; LASRR — LA reservoir strain rate; LASRCD — LA conduit 
strain rate
64 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 1
ejection fraction (LVEF), LV volume and GLS were 
similar between the groups (Table 2).
Echocardiographic parameters versus 
CHA2DS2-VASc score in risk stratification 
of adverse events 
Table 3 shows how each echocardiographic 
parameter was tested against CHA2DS2-VASc score 
in separate multivariate Cox regression models. 
For overall adverse cardiac events (a composite 
of cardiac death, HF exacerbation and ischemic 
stroke), LVMi, E/e’, E, and LAVi remain independ-
ent discriminators and outperform CHA2DS2-VASc 
score. For HF exacerbation, E, E/e’ and LVMi, but 
not CHA2DS2-VASc score, possess abilities in risk 
stratification. As for ischemic stroke, E and E/e’ 
show added value to CHA2DS2-VASc score.
Figure 2 shows the ability of LVMi, E/e’, E, 
LAVi and CHA2DS2-VASc score to predict overall 
cardiac events, HF progression and stroke. In 
general, although the discriminative power of 
echocardiographic parameters was modest based 
on the area under curve, yet they retain superior-
ity when compared to CHA2DS2-VASc score in: 
(1) overall prognosis (LVMi, E/e’, E and LAVi), 
(2) HF exacerbation (LVMi, E/e’), and (3) ischemic 
stroke prediction (E/e’) (p < 0.05). 
Incremental value of echocardiographic  
parameters over CHA2DS2-VASc score  
for predicting future cardiac events 
For overall cardiac events, the sequential ad-
dition of LAVi, E, E/e’ and LVMi to the previous 
model improved the predictive power in nested 
regression analysis (Fig. 3A). For HF progression, 
the addition of E/e’ and LVMi to CHA2DS2-VASc 
score based model offered significant incremental 
value (Fig. 3B). As for ischemic stroke, whether the 
addition of E or E/e’ on top of CHA2DS2-VASc score 
based model provided additional value (Fig. 3C). 
Kaplan-Meier analysis showed better overall 
event-free survival among patients without LVH, 
without elevated LV filling pressure (E/e’ ≥ 15), and 
with normal LV filling pressure (E/e’ < 8), as well 
as those with less enlarged LA (LAVi < median 
value, 43.8 mL/m2) (all Log-rank p < 0.05; Fig. 4). 
As for HF, the presence of LVH or abnormal LV 
filling pressure (E/e’ ≥ 8) displayed poor survival 
(Supplementary Figure 1). For ischemic stroke, 
the presence of E/e’ ≥ 15 predicted worse event-
free survival (Supplementary Figure 2).
Subgroup analyses were also performed by 
stratifying all patients by the CHA2DS2-VASc score 
into: ≤ 1 (n = 48), 2–4 (n=163), and ≥ 5 (n = 41) to 
see whether echocardiographic parameters provide 
additional value (Table 4). For overall prognosis, 
E and E/e’ are significant factors in patients with 
low (≤ 1) CHA2DS2-VASc score; LVEDVi, LVMi, 
E, E/e’ and LAVi are significant in patients with 
intermediate CHA2DS2-VASc score (between 
2 and 4). LVMi is the most powerful factor in this 
intermediate group (adjusted for age, LVEDVi, E, 
and LAVi). For HF progression, E is significant in 
low (≤ 1) CHA2DS2-VASc score group; LVEDVi, 
LVESVi, LVMi, and E/e’ are significant in the in-
termediate group. LVMi is again the most powerful 
factor in this intermediate group (adjusted for age, 
LVEDVi, and E/e’). As for ischemic stroke predic-
tion, E/e’ and LAeR are significant factors in the low 
CHA2DS2-VASc score group. LAVi is significant 
in the intermediate group. In patients with high 
(≥ 5) CHA2DS2-VASc score, no echocardiographic 
indexes remain significant for any prognosis.
Reproducibility
Intraobserver variability values for echocar-
diographic parameters were 6.4–8.8%. The ICCs 
were 0.92–0.97. Corresponding interobserver 
variability values were 7.5–11.0% with an ICC of 
0.90–0.96.
Discussion
There were three major findings in the pre-
sent study: (1) echocardiographic parameters 
outperform CHA2DS2-VASc score in prophesying 
overall cardiac events and HF progression, there-
fore compensate the deficiency of CHA2DS2-VASc 
score in this regard; (2) E/e’ and LVMi are the most 
powerful indexes to discriminate overall cardiac 
events and HF; (3) although CHA2DS2-VASc score 
performs well in stroke prediction, the addition of 
E and E/e’ further strengthens risk stratification. 
E/e’ is particularly useful in low CHA2DS2-VASc 
score (≤ 1). Patients with E/e’ ≥ 15 are at higher risk.
Previous studies
Atrial fibrillation independently adds risks 
to future cardiac events including death, stroke, 
myocardial infarction and HF exacerbation [3]. 
Most efforts have been exerted on stroke predic-
tion and prevention, leading to the refinement of 
CHADS2 score to CHA2DS2-VASc score as well as 
the emergence of new-generation oral anticoagu-
lants. On the other hand, the incidence of HF in AF 
patients varies from 1.7% to more than 10% per 
year, meaning that AF related HF is an important 
clinical comorbid condition which deserves more 
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Figure 2. The predictive power of echocardiographic in-
dexes and CHA2DS2-VASc score for future cardiovascu-
lar events. Receiver operating characteristic curves for 
prediction of overall adverse cardiac events (A), heart 
failure (B) and stroke (C); AUC — area under curve; 
CI — confidence interval.
attention [17]. Although the guideline does empha-
size on preventing HF by rate and rhythm control, 
little is known about the risk stratifying model in 
gauging HF progression in AF [5]. 
Previous studies showed that CHA2DS2-VASc 
score has been reported to be of value in predicting 
AF-associated mortality, perioperative mortality, 
and cardiovascular hospitalization [3, 4, 18–20]. 
Nevertheless, its role in prediction of adverse 
outcome other than stroke was not established. 
Recently, a clinical risk score (ARC2H score) for 
the prediction of HF was explored by a group of 
Japanese researchers by assigning points to age 
≥ 72 years old, heart rate ≥ 80 bpm, hypertension, 
and history of HF [17]. In the same study, the 
CHADS2 score was not found to be related to the 
incidence of HF.
Echocardiographic parameters are promising 
risk-stratification tools because of convenience, 
noninvasiveness, timeliness and reproducibility. In 
AF, several factors aggravate hemodynamic disar-
rangement, including rapid ventricular rate and loss 
of coordinated atrial contraction, leading to short-
ened LV filling, inefficient atrial emptying, a raised 
LA pressure, and impaired forward cardiac output 
with HF symptoms [21]. This effect is even more 
pronounced in patients with reduced LV compliance 
whose atrial contraction contributes significantly to 
LV filling. This implies that echocardiography may 
fill the diagnostic void in risk stratification. Several 
parameters have been reported useful in prognos-
tication in AF, such as E/e’, LAVi, and LVH [6, 9, 
22–25]. Nonetheless, these indicators have not 
been tested directly against CHA2DS2-VASc score.
The present study
It was demonstrated that echocardiographic 
parameters (LVMi, E, E/e’ and LAVi) outperform 
CHA2DS2-VASc score in predicting overall prog-
nosis and HF progression. Also shown was their 
added value (E, E/e’) on top of CHA2DS2-VASc 
score in stroke prediction, especially for patients 
with low CHA2DS2-VASc score (≤ 1). Patients hav-
ing E/e’ ≥ 15 are at higher risk of stroke. In other 
words, with similar heart rate, blood pressure, LV 
volume, LVEF and anticoagulant use, those with 
more advanced LVH, greater E, E/e’ and LAVi suf-
fered from detrimental prognosis in this study. The 
finding is reasonable and suggests factors reflecting 
adaptive consequences caused by increased hemo-
dynamic load in AF bare prognostic value. Secondly, 
particular attention should be paid to AF related 
HF exacerbation. With an average CHA2DS2-VASc 
score 2.90 ± 1.63 and a nationwide underuse of 
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anticoagulants, it was observed that there were 
more HF events than stroke. This implies that HF 
is as important as stroke in AF. Since CHA2DS2- 
-VASc score is insufficient in the prediction of HF, 
echocardiographic indexes may offer more clues. 
Thirdly, deformation parameters (LV GLS and LA 
strain) failed to show prognostication in this study, 
although the degree of impaired deformation was in 
agreement with prior AF studies [26]. A plausible 
explanation was that different loading condition and 
disease process may affect the results. When com-
pared to prior work, more advanced LVH, smaller 
LAVi, better LAEF and LA deformation were 
noted here, which may also explain the differences 
in prognostication provided by LA deformation 
parameters [14]. The usefulness of deformation 
imaging in well-controlled AF patients await more 
studies to confirm this. Lastly, we observed a high 
incidence of adverse cardiac events (29%). Due to 
the retrospective nature of this study, we can only 
presume that suboptimal medication use, patient 
compliance and a higher prevalence of hyperten-
sion may be possible reasons. 
Clinical implications
The present findings offer several potential 
implications. First, refining risk assessment for fu-
ture cardiovascular events is possible, particularly 
in HF progression, which contributed to the major-
ity of the events that were observed. For ischemic 
stroke, elevated LV filling pressure signifies higher 
risk in addition to CHA2DS2-VASc score. While it 
is difficult to make blanket statements about in-
dividual risk, echocardiographic parameters may 
provide added information. Second, by improving 
multifaceted risk evaluation with the aid of nonin-
vasive imaging, high risk population may warrant 
tailored and aggressive management (strict heart 
rate control, balance in volume status and antico-
agulant use). Third, routine echocardiography is 
therefore needed because CHA2DS2-VASc score-
guided anticoagulation therapy could not reduce 
HF progression. Notably, these indexes (LVMi, 
E, E/e’, LAVi) are appealing in clinical practice 
given their generalization, vendor-independency, 
and easiness in measurement. These parameters 
might be used as surrogate markers for guiding 
aggressive treatment to prevent HF in AF. The 
presented findings also suggest that diastology 
may be a key mechanism for future outcome in AF. 
Further studies are required to confirm whether 
these parameters can guide treatment strategies.
Limitations of the study
First, this single-center study was limited in 
the number of participants and was not population 
based. Patients were excluded whose underlying 
disease might engender an adverse outcome, in-
Figure 3. Incremental value of echocardiographic parameters for predicting future cardiovascular events. Nested 
regression models for predicting overall adverse cardiac events (A), heart failure (B), and ischemic stroke (C). The 
first step consisted of CHA2DS2-VASc score. Then left atrial volume index (LAVi), peak mitral early filling velocity (E), 
peak early filling velocity to tissue Doppler mitral annular early diastolic velocity ratio (E/e’) and left ventricular volume 
index (LVMi) were successively included in the next steps.
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Figure 4. Kaplan-Meier curves for overall adverse cardiac events. Prognostic differences were shown between sub-
groups stratified by: A. The presence of left ventricular hypertrophy (LVH); B. The median value of left atrial volume 
index (LAVi) (43.8 mL/m2); C. E/e’ with a cutoff of 8; D. E/e’ with a cutoff of 15.
cluding significant valvular heart disease, cardio-
myopathy, advanced HF, and major organ failure. 
Thus, the generalizability may be limited. Second, 
the duration of AF and HAS-BLED score wasnot 
taken into account, which may be a source of bias. 
Third, the medication was not randomly controlled, 
and the anticoagulation therapy was underused 
(reflecting real world status in Taiwan). Yet there 
was no association between all medication and 
outcome. Although the baseline heart rate showed 
no relevance in prediction of outcome in the stud-
ied population (average heart rate 83.5 ± 18.5 
bpm), it is of interest whether rigorous heart rate 
control might help in preventing HF progression. 
Fourth, our samples included patients with NYHA 
functional classification I, II, and LV systolic dys-
function. However, NYHA functional classification 
and LVEF were similar in patients with or without 
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events. Besides, the subgroup analysis performed 
in patients with preserved LVEF (EF ≥ 50%) 
showed that LVMi, E, and E/e’ remained superior 
over the CHA2DS2-VASc score in terms of overall 
prognosis (Table 5). Fifth, samples had a relatively 
rapid heart rate. Yet the range of heart rate was 
in line with the lenient rate control strategy. The 
relationship between heart rate and HF in AF also 
remains controversial [5, 17]. Finally, stroke was 
evaluated by the computed tomography imaging 
and not by magnetic resonance imaging.
Conclusions
In permanent NVAF, echocardiographic param-
eters provide better discrimination over CHA2DS2- 
-VASc score in overall prognosis and HF. For stroke 
prediction, E/e’ adds value to CHA2DS2-VASc score. 
These findings may assist in refining risk stratifica-
tion in NVAF. 
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